Alnylam Pharmaceuticals this week announced positive interim data from a phase I study of its subcutaneously delivered TTR amyloidosis treatment ALN-TTRsc, which show the drug can cut levels of its disease-causing protein by roughly 90 percent.

During a conference call, Alnylam CEO John Maraganore touted the results as establishing "a new benchmark for consistent and sustained TTR knockdown" when it comes to RNA-based ATTR treatments, and that the company would aim for this target in all future studies of ALN-TTRsc.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.